Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald J Diamond

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Postgraduate Medicine|November 30, 2006
Recovery from a psychiatrist's viewpointRonald J Diamond
Administration and Policy in Mental Health|January 11, 2007
The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophreniaMarion A Becker, M Scott Young, Ezra Ochshorn, et al.
Pharmacoeconomics|January 19, 2006
Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USANatalie C Edwards, Julie C Locklear, Marcia F T Rupnow, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|August 13, 2008
Using non-feature films to teach diversity, cultural competence, and the DSM-IV-TR outline for cultural formulationRussell F Lim, Ronald J Diamond, Jacquelyn B Chang, et al.
Pharmacoeconomics|April 20, 2005
Cost-effectiveness model of long-acting risperidone in schizophrenia in the USNatalie C Edwards, Marcia F T Rupnow, Chris L Pashos, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Postgraduate Medicine|November 30, 2006
Recovery from a psychiatrist's viewpointRonald J Diamond
Administration and Policy in Mental Health|January 11, 2007
The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophreniaMarion A Becker, M Scott Young, Ezra Ochshorn, et al.
Pharmacoeconomics|January 19, 2006
Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USANatalie C Edwards, Julie C Locklear, Marcia F T Rupnow, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|August 13, 2008
Using non-feature films to teach diversity, cultural competence, and the DSM-IV-TR outline for cultural formulationRussell F Lim, Ronald J Diamond, Jacquelyn B Chang, et al.
Pharmacoeconomics|April 20, 2005
Cost-effectiveness model of long-acting risperidone in schizophrenia in the USNatalie C Edwards, Marcia F T Rupnow, Chris L Pashos, et al.
Pageof 1